VYGR Insider Trading

Insider Ownership Percentage: 6.39%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $130,797.39

Voyager Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Voyager Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Voyager Therapeutics Share Price & Price History

Current Price: $3.27
Price Change: Price Increase of +0.19 (6.17%)
As of 07/16/2025 05:00 PM ET

This chart shows the closing price history over time for VYGR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AugSepOctNovDecJanFebMarAprMayJunJul$3.27Closing price on 07/16/25:

SEC Filings (Institutional Ownership Changes) for Voyager Therapeutics (NASDAQ:VYGR)

48.03% of Voyager Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VYGR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$3.37Mbought$1.09MsoldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5M$0$5MTotal InflowsTotal Outflows
Voyager Therapeutics logo
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Read More on Voyager Therapeutics

Today's Range

Now: $3.27
Low: $3.15
High: $3.32

50 Day Range

MA: $3.19
Low: $2.72
High: $3.60

52 Week Range

Now: $3.27
Low: $2.65
High: $9.55

Volume

621,420 shs

Average Volume

489,560 shs

Market Capitalization

$180.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Who are the company insiders with the largest holdings of Voyager Therapeutics?

Voyager Therapeutics' top insider investors include:
  1. Alfred Sandrock (CEO)
  2. Peter P Pfreundschuh (CFO)
  3. Robin Swartz (COO)
  4. Todd Alfred Carter (Insider)
  5. Sandell Jacquelyn Fahey (Insider)
Learn More about top insider investors at Voyager Therapeutics.